Search

Your search keyword '"Dunleavy, Kieron"' showing total 781 results
Start Over Author "Dunleavy, Kieron"
781 results on '"Dunleavy, Kieron"'

1. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial

Author

Melani, Christopher, Dowdell, Kennichi, Pittaluga, Stefania, Dunleavy, Kieron, Roschewski, Mark, Song, Joo Y, Calattini, Sara, Kawada, Jun-ichi, Price, David A, Chattopadhyay, Pratip K, Roederer, Mario, Lucas, Andrea N, Steinberg, Seth M, Jaffe, Elaine S, Cohen, Jeffrey I, and Wilson, Wyndham H

Published
2023
Full Text
View/download PDF

5. Evolving molecular classification of aggressive B‐cell lymphoma.

Author

Alig, Stefan K, Chapuy, Björn, Ennishi, Daisuke, Dunleavy, Kieron, and Hodson, Daniel J

Subjects
NOSOLOGY, DIFFUSE large B-cell lymphomas, TUMOR microenvironment, MEDICAL research, LYMPHOMAS
Abstract

This review aims to provide an overview of the latest developments in the classification and molecular understanding of aggressive B‐cell lymphomas, specifically focusing on diffuse large B‐cell lymphoma (DLBCL) and high‐grade B‐cell lymphoma (HGBL). Advances in molecular techniques have led to novel ways to classify these lymphomas based on clinical, histological, transcriptional, and genetic properties. While these methods have predominantly focused on the malignant compartment, recent studies emphasize the value of profiling the tumour microenvironment for a more comprehensive disease classification. Additionally, the integration of liquid biopsies represents a promising advancement, offering less invasive and dynamic insights into tumour characteristics and treatment response. Although molecular profiles are not yet routinely used to guide therapy, emerging data highlight their potential to predict responses to novel treatments. It is our belief that integrating molecular profiling and liquid biopsies into clinical practice and research now will pave the way for more personalized and effective therapies in the future. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

8. Vaccination of Adults With Cancer: ASCO Guideline

Author

Kamboj, Mini, primary, Bohlke, Kari, additional, Baptiste, Deana M., additional, Dunleavy, Kieron, additional, Fueger, Abbey, additional, Jones, Lee, additional, Kelkar, Amar H., additional, Law, Lisa Y., additional, LeFebvre, Kristine B., additional, Ljungman, Per, additional, Miller, Eric D., additional, Meyer, Larissa A., additional, Moore, Heather N., additional, Soares, Heloisa P., additional, Taplitz, Randy A., additional, Woldetsadik, Edom S., additional, and Kohn, Elise C., additional

Published
2024
Full Text
View/download PDF

14. DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation

Author

Dimitriades, Victoria R, Devlin, Vincent, Pittaluga, Stefania, Su, Helen C, Holland, Steven M, Wilson, Wyndham, Dunleavy, Kieron, Shah, Nirali N, and Freeman, Alexandra F

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hematology, Prevention, Aetiology, 2.1 Biological and endogenous factors, DOCK8, lymphomatoid granulomatosis, lymphomatous granulomatosis, eBV lymphoproliferation, bone marrow transplantation, Paediatrics and Reproductive Medicine, Other Medical and Health Sciences, Paediatrics
Abstract

Dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal recessive, combined immunodeficiency within the spectrum of hyper-IgE syndromes. Epstein-Barr virus-positive lymphomatoid granulomatosis (LYG) (EBV + LYG) is a rare diagnosis and a previously unreported presentation of DOCK8 deficiency. A 10-year-old girl was initially evaluated for mild eczema and recurrent sinopulmonary infections. She had normal immunoglobulins with elevated IgE, poor polysaccharide response with low switched memory B cells, low CD4 count, and normal mitogen and antigen responses. Despite clinical improvement following immunoglobulin replacement, a prolonged cough prompted a CT scan, which showed nodules. Biopsy identified a Grade 2 EBV + LYG. Due to an inadequate response with chemotherapy, further workup for primary immunodeficiency was performed. With her symptoms of eczema and IgE elevation, along with her brother's history of recurrent sinopulmonary infections and warts, targeted sequencing of DOCK8 was performed revealing compound heterozygous mutations for the two siblings. Both patients were successfully transplanted with resolution of the LYG and warts, respectively. This is the first reported case of LYG in DOCK8 deficiency. The EBV-driven lymphoproliferative disease along with the infection history in the brother led to the diagnosis of DOCK8 deficiency and curative hematopoietic stem cell transplants.

Published
2017

15. Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Author

Fowler, Nathan H, Cheah, Chan Yoon, Gascoyne, Randy D, Gribben, John, Neelapu, Sattva S, Ghia, Paolo, Bollard, Catherine, Ansell, Stephen, Curran, Michael, Wilson, Wyndham H, O'Brien, Susan, Grant, Cliona, Little, Richard, Zenz, Thorsten, Nastoupil, Loretta J, and Dunleavy, Kieron

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Hematology, Rare Diseases, Cancer, Lymphoma, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Animals, B-Lymphocytes, Biomarkers, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Immunotherapy, Leukemia, B-Cell, Lymphoma, B-Cell, Molecular Targeted Therapy, Neoplasm Grading, Neoplasm Staging, Signal Transduction, Tumor Escape, Tumor Microenvironment, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

The tumor microenvironment is the cellular and molecular environment in which the tumor exists and with which it continuously interacts. In B-cell lymphomas, this microenvironment is intriguing in that it plays critical roles in the regulation of tumor cell survival and proliferation, fostering immune escape as well as the development of treatment resistance. The purpose of this review is to summarize the proceedings of the Second Annual Summit on the Immune Microenvironment in Hematologic Malignancies that took place on September 11-12, 2014 in Dublin, Ireland. We provide a timely overview of the composition and biological relevance of the cellular and molecular microenvironment interface and discuss the role of interactions between the microenvironment and neoplastic cells in a variety of B-cell lymphomas. In addition, we focus on various novel therapeutic strategies that target the tumor microenvironment, including agents that modulate B-cell receptor pathways and immune-checkpoints, chimeric antigen receptor T cells and immunomodulatory agents.

Published
2016

16. Burkitt Lymphoma

Author

Dunleavy, Kieron, Chamuleau, Martine, Dreyling, Martin, Series Editor, Lenz, Georg, editor, and Salles, Gilles, editor

Published
2019
Full Text
View/download PDF

21. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Author

Dunleavy, Kieron, Fanale, Michelle A, Abramson, Jeremy S, Noy, Ariela, Caimi, Paolo Fabrizio, Pittaluga, Stefania, Parekh, Samir, Lacasce, Ann, Hayslip, John W, Jagadeesh, Deepa, Nagpal, Sunil, Lechowicz, Mary Jo, Gaur, Rakesh, Lucas, Andrea, Melani, Christopher, Roschewski, Mark, Steinberg, Seth M, Jaffe, Elaine S, Kahl, Brad, Friedberg, Jonathan W, Little, Richard F, Bartlett, Nancy L, and Wilson, Wyndham H

Published
2018
Full Text
View/download PDF

25. Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Author

Lakhotia, Rahul, primary, Dunleavy, Kieron, additional, Abramson, Jeremy S., additional, Link, Brian K., additional, Powell, Bayard L., additional, Melani, Christopher, additional, Lucas, Andrea N., additional, Steinberg, Seth M., additional, Friedberg, Jonathan W., additional, Kahl, Brad S., additional, Little, Richard F., additional, Bartlett, Nancy L., additional, Noy, Ariela, additional, Wilson, Wyndham H., additional, and Roschewski, Mark, additional

Published
2023
Full Text
View/download PDF

26. POSTER: ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Author

Simard, Jillian, primary, Phelan, James D, additional, Melani, Christopher, additional, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Muppidi, Jagan R, additional, Lionakis, Michail S, additional, Peer, Cody, additional, Pradhan, Amynah, additional, Holdhoff, Matthias, additional, Swinnen, Lode J, additional, Dunleavy, Kieron, additional, Lai, Catherine, additional, Ibrahimi, Sami, additional, Glantz, Michael, additional, Butman, John A, additional, Johnson, Kim, additional, Steinberg, Seth M, additional, Figg, William D, additional, Jaffe, Elaine S, additional, Staudt, Louis M, additional, Wilson, Wyndham H, additional, and Roschewski, Mark, additional

Published
2023
Full Text
View/download PDF

27. ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Author

Simard, Jillian, primary, Phelan, James D, additional, Melani, Christopher, additional, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Muppidi, Jagan R, additional, Lionakis, Michail S, additional, Peer, Cody, additional, Pradhan, Amynah, additional, Holdhoff, Matthias, additional, Swinnen, Lode J, additional, Dunleavy, Kieron, additional, Lai, Catherine, additional, Ibrahimi, Sami, additional, Glantz, Michael, additional, Butman, John A, additional, Johnson, Kim, additional, Steinberg, Seth M, additional, Figg, William D, additional, Jaffe, Elaine S, additional, Staudt, Louis M, additional, Wilson, Wyndham H, additional, and Roschewski, Mark, additional

Published
2023
Full Text
View/download PDF

31. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Author

Lionakis, Michail S., Dunleavy, Kieron, Roschewski, Mark, Widemann, Brigitte C., Butman, John A., Schmitz, Roland, Yang, Yandan, Cole, Diane E., Melani, Christopher, Higham, Christine S., Desai, Jigar V., Ceribelli, Michele, Chen, Lu, Thomas, Craig J., Little, Richard F., Gea-Banacloche, Juan, Bhaumik, Sucharita, Stetler-Stevenson, Maryalice, Pittaluga, Stefania, Jaffe, Elaine S., Heiss, John, Lucas, Nicole, Steinberg, Seth M., Staudt, Louis M., and Wilson, Wyndham H.

Published
2017
Full Text
View/download PDF

34. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)

Author

Kline, Kathryn, primary, Chen, Wengen, additional, Kallen, Michael E., additional, Koka, Rima, additional, Omili, Destiny, additional, Fan, Xiaoxuan, additional, Iraguha, Thierry, additional, Gebru, Etse, additional, Dishanthan, Nishanthini, additional, Baker, Jillian M., additional, Dietze, Kenneth A., additional, Yared, Jean A., additional, Hankey, Kim, additional, Dahiya, Saurabh, additional, Niederhaus, Silke V., additional, Dunleavy, Kieron, additional, Hardy, Nancy M., additional, Luetkens, Tim, additional, Rapoport, Aaron P., additional, and Atanackovic, Djordje, additional

Published
2023
Full Text
View/download PDF

39. Data from Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

Author

Weniger, Marc A., primary, Rizzatti, Edgar G., primary, Pérez-Galán, Patricia, primary, Liu, Delong, primary, Wang, Qiuyan, primary, Munson, Peter J., primary, Raghavachari, Nalini, primary, White, Therese, primary, Tweito, Megan M., primary, Dunleavy, Kieron, primary, Ye, Yihong, primary, Wilson, Wyndham H., primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Tables 1-5 from Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

Author

Weniger, Marc A., primary, Rizzatti, Edgar G., primary, Pérez-Galán, Patricia, primary, Liu, Delong, primary, Wang, Qiuyan, primary, Munson, Peter J., primary, Raghavachari, Nalini, primary, White, Therese, primary, Tweito, Megan M., primary, Dunleavy, Kieron, primary, Ye, Yihong, primary, Wilson, Wyndham H., primary, and Wiestner, Adrian, primary

Published
2023
Full Text
View/download PDF

41. Zuma-25: A Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) Chimeric Antigen Receptor T-Cell Therapy in Adult Patients with Relapsed/Refractory Rare B-Cell Malignancies

Author

Eichhorst, Barbara, primary, Dunleavy, Kieron, additional, Tiacci, Enrico, additional, Buske, Christian, additional, Jain, Nitin, additional, Castillo, Jorge J., additional, Rossi, Davide, additional, Woolven, Kate, additional, Masouleh, Behzad Kharabi, additional, Peng, Weimin, additional, Schuberth, Petra C., additional, Domper, Neus, additional, Wolthers, Benjamin O., additional, and Palomba, M. Lia, additional

Published
2023
Full Text
View/download PDF

49. Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)

Author

Kline, Kathryn, Chen, Wengen, Kallen, Michael E., Koka, Rima, Omili, Destiny, Fan, Xiaoxuan, Iraguha, Thierry, Gebru, Etse, Dishanthan, Nishanthini, Baker, Jillian M., Dietze, Kenneth A., Yared, Jean A., Hankey, Kim, Dahiya, Saurabh, Niederhaus, Silke V., Dunleavy, Kieron, Hardy, Nancy M., Luetkens, Tim, Rapoport, Aaron P., and Atanackovic, Djordje

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication following kidney transplantation, and there is a critical and unmet need for PTLD treatments associated with more pronounced and durable responses. To date, reports on the use of CD19-targeted chimeric antigen receptor (CAR) T (CAR-T) cells in patients after solid organ transplant (SOT) have been anecdotal, clinical presentations and outcomes have been heterogenous, and a longitudinal analysis of CAR-T cell expansion and persistence in PTLD patients has not been reported. Our report describes a patient with a history of renal transplant who received CD19-directed CAR-T cell therapy for the treatment of refractory PTLD, diffuse large B cell lymphoma (DLBCL)-type. We show that even with the background of prolonged immunosuppression for SOT, it is possible to generate autologous CAR-T products capable of expansion and persistence in vivo, without evidence of excess T-cell exhaustion. Our data indicate that CAR-T cells generated from a SOT recipient with PTLD can yield deep remissions without increased toxicity or renal allograft dysfunction. Future clinical studies should build on these findings to investigate CAR-T therapy, including longitudinal monitoring of CAR-T phenotype and function, for PTLD in SOT recipients.

Published
2023
Full Text
View/download PDF

50. Genomic profiling for clinical decision making in lymphoid neoplasms

Author

de Leval, Laurence, primary, Alizadeh, Ash A., additional, Bergsagel, P. Leif, additional, Campo, Elias, additional, Davies, Andrew, additional, Dogan, Ahmet, additional, Fitzgibbon, Jude, additional, Horwitz, Steven M., additional, Melnick, Ari M., additional, Morice, William G., additional, Morin, Ryan D., additional, Nadel, Bertrand, additional, Pileri, Stefano A., additional, Rosenquist, Richard, additional, Rossi, Davide, additional, Salaverria, Itziar, additional, Steidl, Christian, additional, Treon, Steven P., additional, Zelenetz, Andrew D., additional, Advani, Ranjana H., additional, Allen, Carl E., additional, Ansell, Stephen M., additional, Chan, Wing C., additional, Cook, James R., additional, Cook, Lucy B., additional, d’Amore, Francesco, additional, Dirnhofer, Stefan, additional, Dreyling, Martin, additional, Dunleavy, Kieron, additional, Feldman, Andrew L., additional, Fend, Falko, additional, Gaulard, Philippe, additional, Ghia, Paolo, additional, Gribben, John G., additional, Hermine, Olivier, additional, Hodson, Daniel J., additional, Hsi, Eric D., additional, Inghirami, Giorgio, additional, Jaffe, Elaine S., additional, Karube, Kennosuke, additional, Kataoka, Keisuke, additional, Klapper, Wolfram, additional, Kim, Won Seog, additional, King, Rebecca L., additional, Ko, Young H., additional, LaCasce, Ann S., additional, Lenz, Georg, additional, Martin-Subero, José I., additional, Piris, Miguel A., additional, Pittaluga, Stefania, additional, Pasqualucci, Laura, additional, Quintanilla-Martinez, Leticia, additional, Rodig, Scott J., additional, Rosenwald, Andreas, additional, Salles, Gilles A., additional, San-Miguel, Jesus, additional, Savage, Kerry J., additional, Sehn, Laurie H., additional, Semenzato, Gianpietro, additional, Staudt, Louis M., additional, Swerdlow, Steven H., additional, Tam, Constantine S., additional, Trotman, Judith, additional, Vose, Julie M., additional, Weigert, Oliver, additional, Wilson, Wyndham H., additional, Winter, Jane N., additional, Wu, Catherine J., additional, Zinzani, Pier L., additional, Zucca, Emanuele, additional, Bagg, Adam, additional, and Scott, David W., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results